Abstract
The first phase III study of tumor-infiltrating lymphocytes in melanoma shows that the cells are more effective than ipilimumab. Compared with the CTLA4 inhibitor, tumor-infiltrating lymphocytes yielded a higher objective response rate and longer progression-free and overall survival.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.